Patients with type 1 diabetes mellitus, ketosis, DKA or acute complications were excluded, and insulin therapy was initiated on day 0, the day before SGLT2 inhibitor administration. This evidence concerns the gene SLC5A2 and type 1 diabetes mellitus.